Genmab is going through a growth spurt and expands on three continents
Genmab keeps expanding its workforce in Europe, the US and Japan to prepare for handling drug commercialization on its own.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
If Genmab's drug tisotumab vedotin is approved in the US in October as expected, the firm will take on its own sales and marketing for the first time.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab spent more than DKK 1 billion in Q1
For subscribers
